| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba15617c44328a17f4a78439467646f8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55583
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55594 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2292
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 |
| filingDate |
2018-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c48b880cc76493ff9a4642e598bc286
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5ab0f0ff02c7393fe2f80288b59b1be |
| publicationDate |
2018-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018138682-A1 |
| titleOfInvention |
Methods and compositions useful for treating cancer |
| abstract |
A cancer immunotherapy method for treating cancer in a patient comprising the steps of: removing lymphocytes from the peripheral blood of the patient; exposing the lymphocytes to one or more of i) a thymosin peptide, ii) a purified immune RNA or DNA. iii) one or more astragalus polysaccharides, iv) one or more letinous edodes polysaccharides, v) a cell wall component of Mycobacterium grannis, Mycobacterium phlei or Mycobaterium subtilis vi) a polysaccharide nucleic acid fraction of bacillus Calmette-Guerin, vii) a transfer factor viii) one or more non steroidal anti inflammatory agents and xi) an enkephalin chosen from methionine enkephalin or leucine enkephalin in vitro and infusing the exposed lymphocytes back into the patient is provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021025551-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11097004-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111450053-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113713026-A |
| priorityDate |
2017-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |